This application responds to RFA-CA-08-504 which is intended to continue support for Phase 1 and 2 treatment studies in adults with primary central nervous system cancers and to continue the activities that were funded initially under RFA CA-04-001. This single, consolidated application from the two currently funded separate adult brain tumor consortia: New Approaches to Brain Tumor Therapy (NABTT) and North American Brain Tumor Consortium (NABTC) is designed to maximize clinical trial efficiency and enhance support for translational research. The Adult Brain Tumor Consortium (ABTC) will capitalize on the scientific expertise and experience that has been nurtured during the previous award periods by retaining the majority of the NABTT and NABTC member institutions as well as clinical trial, pharmacology, biostatistics, and neuropathology leadership. The Co-Principal Investigators of the ABTC (Stuart Grossman and Michael Prados) have directed the activities of NABTT and NABTC since their inception in 1994. ABTC will utilize the skills and experience of The NABTT Operations Office (Stuart Grossman and Joy Fisher), the NABTC biostatistician (Kathleen Lamborn), pharmacologists from NABTT and NABTC (Jeff Supko and John Kuhn), and neuro-imaging (Greg Sorensen and Sarah Nelson) and neuropathology (Ken Aldape) experts. Based on predetermined criteria, the ABTC Steering Committee will evaluate potential member sites, dismiss underperforming member sites, and evaluate competitive applications and award funds for pharmacologic, imaging, and correlative biology research. ABTC's committee structure will focus on interactions with the NIH, SPOREs, cooperative groups, institutional translational research, pharmaceutical companies, and novel multidisciplinary approaches. An experienced and international External Advisory Board will provide valuable input to ABTC. This newly consolidated consortium will strive to develop more effective therapies for adult brain tumors by: 1) safely and efficiently introducing novel anticancer agents into the treatment of high grade primary brain tumors through the conduct of Phase 1-2 clinical trials, 2) Proactively seeking collaborations with other NCI-funded clinical trials mechanisms and researchers devoted to finding promising new treatment approaches for adult brain tumors;and 3) Incorporating pharmacokinetic and pharmacodynamic endpoints (including imaging and translational laboratory studies) as appropriate into Phase 1-2 studies.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Research Project--Cooperative Agreements (U01)
Project #
Application #
Study Section
Special Emphasis Panel (ZCA1-SRRB-Y (O2))
Program Officer
Timmer, William C
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Johns Hopkins University
Internal Medicine/Medicine
Schools of Medicine
United States
Zip Code
Taylor, Jennie W; Parikh, Mili; Phillips, Joanna J et al. (2018) Phase-2 trial of palbociclib in adult patients with recurrent RB1-positive glioblastoma. J Neurooncol 140:477-483
Blakeley, Jaishri O; Grossman, Stuart A; Chi, Andrew S et al. (2018) Phase II Study of Iniparib with Concurrent Chemoradiation in Patients with Newly Diagnosed Glioblastoma. Clin Cancer Res :
Kleinberg, L R; Stieber, V; Mikkelsen, T et al. (2015) Outcome of Adult Brain Tumor Consortium (ABTC) prospective dose-finding trials of I-125 balloon brachytherapy in high-grade gliomas: challenges in clinical trial design and technology development when MRI treatment effect and recurrence appear similar. J Radiat Oncol 4:235-241
Blakeley, Jaishri O; Grossman, Stuart A; Mikkelsen, Tom et al. (2015) Phase I study of iniparib concurrent with monthly or continuous temozolomide dosing schedules in patients with newly diagnosed malignant gliomas. J Neurooncol 125:123-31
Streiff, Michael B; Ye, Xiaobu; Kickler, Thomas S et al. (2015) A prospective multicenter study of venous thromboembolism in patients with newly-diagnosed high-grade glioma: hazard rate and risk factors. J Neurooncol 124:299-305
Hale, James S; Otvos, Balint; Sinyuk, Maksim et al. (2014) Cancer stem cell-specific scavenger receptor CD36 drives glioblastoma progression. Stem Cells 32:1746-58
Wen, Patrick Y; Chang, Susan M; Lamborn, Kathleen R et al. (2014) Phase I/II study of erlotinib and temsirolimus for patients with recurrent malignant gliomas: North American Brain Tumor Consortium trial 04-02. Neuro Oncol 16:567-78
Holdhoff, Matthias; Ambady, Prakash; Abdelaziz, Ahmed et al. (2014) High-dose methotrexate with or without rituximab in newly diagnosed primary CNS lymphoma. Neurology 83:235-9
Lathia, Justin D; Li, Meizhang; Sinyuk, Maksim et al. (2014) High-throughput flow cytometry screening reveals a role for junctional adhesion molecule a as a cancer stem cell maintenance factor. Cell Rep 6:117-29
Shonka, Nicole; Piao, Yuji; Gilbert, Mark et al. (2013) Cytokines associated with toxicity in the treatment of recurrent glioblastoma with aflibercept. Target Oncol 8:117-25

Showing the most recent 10 out of 22 publications